Skip to content
HowShorted

Acurx Pharmaceuticals, Inc. short interest in 2022

In 2022, Acurx Pharmaceuticals, Inc.'s disclosed short interest ran from 1.34% of shares outstanding on 14 Jan 2022 to 0.20% on 30 Dec 2022, a change of -1.14 percentage points. The year's high was 1.34% on 14 Jan 2022 and its low 0.19% on 31 Oct 2022, averaging 0.47% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.59 days on 14 Apr 2022. Full history: Acurx Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Acurx Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
1.34% (14 Jan 2022)
End of year
0.20% (30 Dec 2022)
Change
-1.14 pp
High
1.34% (14 Jan 2022)
Low
0.19% (31 Oct 2022)
Average
0.47%
Highest days to cover
10.59 (14 Apr 2022)
SEC filings marked
9

Every report in 2022

Acurx Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20221.34%5.73
31 Jan 20220.95%1.43
15 Feb 20220.91%6.34
28 Feb 20220.42%1.86
15 Mar 20220.46%2.56
31 Mar 20221.09%3.3710-K filed, results (8-K)
14 Apr 20220.85%10.59
29 Apr 20220.34%3.56
13 May 20220.48%2.2110-Q filed, results (8-K)
31 May 20220.47%6.20
15 Jun 20220.55%1.69
30 Jun 20220.39%3.64
15 Jul 20220.22%1.86
29 Jul 20220.41%5.24results (8-K)
15 Aug 20220.32%1.0010-Q filed, results (8-K)
31 Aug 20220.21%1.11
15 Sep 20220.23%1.00
30 Sep 20220.34%1.45
14 Oct 20220.26%2.54
31 Oct 20220.19%1.14
15 Nov 20220.20%1.0010-Q filed, results (8-K)
30 Nov 20220.20%1.26
15 Dec 20220.25%1.14
30 Dec 20220.20%1.00

See also: Acurx Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.